Opendata, web and dolomites

TANTUMorNEUVACCINE SIGNED

Neutrophil subtypes: distinct cellular targets for therapeutic intervention

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "TANTUMorNEUVACCINE" data sheet

The following table provides information about the project.

Coordinator
FONDAZIONE PER L ISTITUTO DI RICERCA IN BIOMEDICINA 

Organization address
address: VIA VINCENZO VELA 6
city: BELLINZONA
postcode: 6500
website: http://www.irb.usi.ch

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 265˙840 €
 EC max contribution 265˙840 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-GF
 Starting year 2017
 Duration (year-month-day) from 2017-10-01   to  2020-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FONDAZIONE PER L ISTITUTO DI RICERCA IN BIOMEDICINA CH (BELLINZONA) coordinator 265˙840.00
2    THE GENERAL HOSPITAL CORPORATION US (BOSTON MA) partner 0.00

Map

 Project objective

In cancer immunotherapy and vaccine field, considerable efforts have been invested to optimize the induction of effector T cells that, by recognizing tumor-specific or pathogen-associated antigens, control tumor cells or infections. Preserving effector T cell function is a major focus of cancer immunotherapy approaches for clinical trials, as is the development of strategies to target regulatory T cells (Tregs) that directly control T cell hypo-responsiveness. In the vaccine field, on the other hand, several strategies have been developed to improve T cell immunogenicity to heterologous antigens expressed by viral vectors. Especially for HIV viral vectors, new vaccine approaches have yielded promising results in primates, although effectiveness was limited in human clinical trials so far. Tumor-associated neutrophils (TAN) participate in the control of human tumor progression. If and how TAN interact with effector Tregs at distinct tumor stages remains to be determined. TAN signals that may regulate the functional state of tumor T cells must be defined. It is also not known whether Tregs interact with TAN and facilitate their functional switch from anti- to pro- tumorigenic state. Distinct neutrophil subtypes are recruited as a result of pro-inflammatory environment during virus infection. Study of the mechanism of neutrophil-dependent control of T cell subset responses to virus-delivered antigens would be of major interest for the generation of viral-based vaccines. The ability of neutrophil subtypes to interact with T cells must be defined to improve the virus-based vaccine efficacy. Our studies could provide: • new treatment strategies that prevent TAN dysfunction, Tregs activation and subsequent effector T cell hyporesponsiveness, and thus increase the effectiveness of cancer immunotherapy • new vaccine approaches to modulate neutrophil subtypes responses to improve antigen-specific T cell responses, and thus increase the effectiveness of HIV vaccines.

 Publications

year authors and title journal last update
List of publications.
2019 Mauro Di Pilato, Edward Y. Kim, Bruno L. Cadilha, Jasper N. Prüßmann, Mazen N. Nasrallah, Davide Seruggia, Shariq M. Usmani, Sandra Misale, Valentina Zappulli, Esteban Carrizosa, Vinidhra Mani, Matteo Ligorio, Ross D. Warner, Benjamin D. Medoff, Francesco Marangoni, Alexandra-Chloe Villani, Thorsten R. Mempel
Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy
published pages: 112-116, ISSN: 0028-0836, DOI: 10.1038/s41586-019-1215-2
Nature 570/7759 2019-10-28

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TANTUMORNEUVACCINE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TANTUMORNEUVACCINE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MITafterVIT (2020)

Unravelling maintenance mechanisms of immune tolerance after termination of venom immunotherapy by means of clonal mast cell diseases

Read More  

ORIGIN (2019)

Origin: reconstructing African prehistory using ancient DNA

Read More  

Topo-circuit (2019)

Exploring topological phenomenon in RF circuits

Read More